Mirap Distab (Mirtazapine)

Mirtazapine is a NaSSA antidepressant used in the management of mood disorders.

• Major depressive disorder: reduces depressive symptoms and improves mood.
• Depressive episodes associated with major depressive disorder: helps alleviate insomnia and anxiety.
• Treatment‑resistant depression (adjunct therapy): may enhance overall therapeutic response when combined with other agents.

• Mirtazapine acts as an antagonist at central presynaptic α2‑adrenergic receptors, increasing norepinephrine release, and blocks 5‑HT2 and 5‑HT3 receptors, enhancing serotonergic neurotransmission while sparing 5‑HT1A receptors. This combined effect contributes to its antidepressant activity.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Sedation: drowsiness, especially at treatment initiation.
• Increased appetite: may lead to weight gain.
• Dry mouth: reduced salivation.
• Constipation: slowed gastrointestinal motility.
• Dizziness: light‑headedness on standing.
• Fatigue: general lack of energy.

Serious or Rare Side Effects

• Agranulocytosis: severe reduction in white blood cells.
• Seizures: rare occurrence of convulsive episodes.
• Hepatotoxicity: potential liver enzyme elevation.
• Suicidal thoughts: emergence of suicidal ideation.
• Stevens‑Johnson syndrome: severe skin reactions.
• Severe neutropenia: marked decrease in neutrophil count.

Before prescribing Mirap Distab, clinicians should consider several safety measures.

• Monitor weight: patients may experience significant weight gain.
• Assess sedation: increased drowsiness can affect daily activities.
• Evaluate hepatic function: drug is metabolized in the liver.
• Avoid abrupt discontinuation: tapering reduces withdrawal risk.
• Use caution in elderly: higher fall risk due to sedation.
• Store at ambient temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• MAO inhibitors: risk of hypertensive crisis and serotonin syndrome.
• Linezolid or other serotonergic agents: potential serotonin syndrome.
• Strong CYP2D6 inhibitors: may increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., benzodiazepines, alcohol): additive sedation.
• CYP3A4 inhibitors (e.g., ketoconazole): may raise drug concentration.
• CYP3A4 inducers (e.g., rifampicin): may reduce efficacy.
• Anticholinergic drugs: may exacerbate dry mouth and constipation.